Evidence brief · Supplement

Huperzine A for Cognition in dementia

Evidence grade C — Variable-quality trials

Overall grade
Grade C
Last revised
1
graded outcome
0
references listed

Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.

1 at grade C — 1 graded row

What is known

Each outcome with its grade (how strong the evidence is, A to D), the size of the effect where the entry records one, and how often studies agree.

  • Cognition in dementiaEvidence grade C

    Variable-quality trials

    Smallmixed

What is uncertain

Read off the same rows as above. Nothing here is added that the entry does not itself record.

  • Thin evidence: Cognition in dementia (grade C).

The evidence in words

The verdict

For cognition in dementia, Huperzine A earns evidence grade C (small effect, mixed consistency) — the evidence is limited or mixed. Variable-quality trials

How it might work

By blocking the enzyme that breaks down acetylcholine, it boosts cholinergic signaling — the same target class as some Alzheimer's drugs.

How to use it

50–200 µg if used; not for casual continuous use.

Safety & cautions

Cholinergic side effects (GI, cramps); additive with cholinesterase-inhibitor drugs — treat it as a drug.

Bottom line

Pharmacologically real but drug-like. Reserve for medical contexts; not a daily 'focus' supplement.

How it is used

As the entry records it, from the studies it summarises. Not a recommendation for you — doses that suit a trial population may not suit you.

Standard
50–200 µg; not continuous casual use.

Goes with

  • Huperzine ARead the full Huperzine A monographEvidence grade C

Entries that share this one's tags or conditions.

Sources

This entry lists no references of its own — it is assembled from the entries it links to, whose sources are on their pages.

Last revised . A grade is this entry's reading of the evidence, not medical advice.